InnoUp Farma
InnoUp Farma is a Spanish clinical-stage biopharmaceutical company developing a patented, orally administered nanoparticle drug-delivery platform, with lead programs INP20 for peanut allergy and INP12 for breast cancer.
- Company typePrivate
- Founded2013
- HeadquartersNoáin, Spain
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What InnoUp Farma does
InnoUp Farma, SL is a Spanish clinical-stage biopharmaceutical company headquartered in Noáin (Navarra), founded in 2013, that develops oral drug delivery solutions based on a proprietary biocompatible nanoparticle platform protected by international patents. The core technology comprises nanoparticles with high bioadhesive capacity that adhere to the intestinal wall and provide sustained release of encapsulated payloads, enabling oral administration of drugs that historically required intravenous delivery and offering mucosal adjuvant capacity for vaccines and immunotherapies. The company has scaled the manufacturing process to validated, reproducible, continuous industrial production. Its pipeline comprises three core programs: INP12, an oral paclitaxel formulation for breast cancer (Phase I approved by competent authorities, with preclinical data showing higher efficacy and lower toxicity than intravenous Taxol); INP20, an oral peanut-extract nanoparticle immunotherapy for peanut allergy (Phase I in development, innocuously in animal studies); and INP30, an oral inactivated SARS-CoV-2 vaccine candidate at the preclinical stage. Beyond the three core programs, the platform has also been applied to a canine dry-eye treatment in partnership with Avizorex Pharma.
The company's revenue model is dual-track: it monetizes the platform through future drug development and licensing arrangements with pharmaceutical partners, and it funds ongoing R&D primarily via non-dilutive public grants from Spanish and EU bodies including CDTI, Ministerio de Ciencia e Innovación, Gobierno de Navarra (FEDER), ICEX-Next, ENISA, AEI, and NextGenerationEU. Two disclosed equity rounds (approximately $2.15M in November 2015 from Inveready and SODENA, and approximately $1.21M in January 2021 led by CDTI with Inveready and SODENA) provide additional capital. The go-to-market motion is enterprise-oriented: licensing partnerships with pharmaceutical companies are positioned as the primary commercialization path, targeting patients with food allergies, breast cancer, and other vaccine-preventable or low-bioavailability-drug conditions.
InnoUp is co-founded and led by Maite Agueros (CEO & co-founder), Manuel Rodríguez-Mariscal (Board Chairman & co-founder), and Prof. Juan M. Irache (Nanomedicine Expert and University of Navarra affiliate), with Jorge Tejero as CFO. It maintains a 11–50-person team anchored by PhD R&D leads and supported by clinical and CMC advisors (Complejo Hospitalario de Navarra, VHIO, University Clinic of Navarra). Strategic and financial partners include Inveready and Sodena (board representation by Sara Secall and María García), Universidad de Navarra, VHIO, Complejo Hospitalario de Navarra, and CerTest Biotec. The company is privately held, has not undergone an IPO or acquisition, and operates primarily in Pamplona/Navarra with a documented European (ICEX-Next) internationalization program.
InnoUp Farma firmographics
Firmographics- Name
- InnoUp Farma
- Legal name
- InnoUp Farma, SL
- Website
- https://innoupfarma.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- InnoUp Farma is a Spanish clinical-stage biopharmaceutical company developing a patented, orally administered nanoparticle drug-delivery platform, with lead programs INP20 for peanut allergy and INP12 for breast cancer.
- Ownership category
- akta.pro rank
InnoUp Farma industry classification
Industry- Product category
- Nanopharmaceuticals / Oral Drug Delivery Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
Keywords
Where InnoUp Farma is headquartered
LocationHeadquarters
- HQ city
- Noáin
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
InnoUp Farma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development and Licensing: Revenue through development of proprietary nanomedicine products through clinical stages and licensing platform technology to pharmaceutical partners.
- Government Grants and Research Funding: The company receives public funding from various government bodies including Ministerio de Ciencia e Innovación, CDTI, Gobierno de Navarra, ICEX, and ENISA for R&D projects including clinical trials and vaccine development.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
InnoUp Farma product offering
Product offeringCore offering
InnoUp Farma is a clinical-stage biopharmaceutical company that develops oral drug delivery products based on a proprietary, patented Nanoparticle Platform of biocompatible, high-bioadhesive particles. It is advancing three programs: INP12 (oral paclitaxel for breast cancer, Phase I approved), INP20 (oral peanut allergy immunotherapy, Phase I in development), and INP30 (oral SARS-CoV-2 vaccine, preclinical). The platform is designed to increase bioavailability, reduce toxicity and enable mucosal vaccination/immunotherapy, and has been scaled to industrial production.
Product overview
InnoUp Farma is a clinical-stage biopharmaceutical company specializing in nanotechnology innovations for oral drug delivery. The company has developed a Nanoparticle Platform protected by international patents, which serves as the core technology for three main products: INP12 (oral paclitaxel for breast cancer treatment), INP20 (peanut allergy oral immunotherapy vaccine), and INP30 (oral COVID-19 vaccine candidate). The platform uses biocompatible nanoparticles with high bioadhesive capacity that stay in contact with the intestinal wall for sustained drug release. The technology enables oral administration of drugs with low bioavailability and mucosal vaccine delivery with adjuvant capacity. The platform has been scaled up to industrial production with validated, reproducible, and continuous manufacturing processes.
Differentiator
Problem solved
Functional benefit
Products and services
- INP12 Clinical-stage oral paclitaxel product based on InnoUp Farma's nanoparticle platform, designed to enable oral administration of a low-bioavailability oncology drug with reduced toxicity and higher preclinical efficacy than intravenous Taxol. Targeted at breast cancer patients requiring chemotherapy.
- INP20 Clinical-stage oral immunotherapy product based on nanoparticle-encapsulated peanut extract for the treatment of peanut allergy, shown to be innocuous in animal studies. Serves as a platform for developing immunotherapeutic products for other food allergies.
- INP30 Preclinical-stage oral vaccine product based on nanoparticle-encapsulated inactivated SARS-CoV-2, being developed to demonstrate immunogenic effect. Serves as a platform for developing oral vaccines against other viruses and bacteria.
- Nanoparticle Platform Proprietary, internationally patented encapsulation platform based on biocompatible nanoparticles with high bioadhesive capacity that stay in contact with the intestinal wall for sustained drug release. Enables oral delivery of low-bioavailability drugs and mucosal adjuvant effects for vaccines/immunotherapies, and has been scaled to industrial production with validated, reproducible and continuous processes. Available for licensing to pharmaceutical partners.
Quantifiable outcome
- Phase I clinical trial for INP12 (paclitaxel) approved by competent authorities
- +3 more outcomes
Companies that use InnoUp Farma
Customer profileSegments3 records
Ideal customer profiles3 records
InnoUp Farma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
InnoUp Farma partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Universidad de NavarracoreAcademic research partner contributing scientific expertise. Co-founders Prof. Juan M. Irache and Prof. Carlos Gamazo are affiliated with University of Navarra.
- Vall d'Hebron Institute of Oncology (VHIO)coreResearch collaboration partner in oncology research and development activities.
- Complejo Hospitalario de NavarracoreClinical research partner with Dr. Ana I. Tabar (allergologist) serving as advisor. Participates in clinical study development.
- Avizorex Pharma S.LminorCollaborative partner in project CANINE-DRYEYE (RTC-2015-4229-1-P02) for development of pharmacological treatment for canine dry eye keratoconjunctivitis.
- Universidad de ZaragozaminorAcademic research partner collaborating with Avizorex Pharma on canine dry eye project.
- CerTest BiotecminorPartner in mRNA vaccine development project against SARS-CoV-2 Delta variant. InnoUp Farma participates in this CDTI-funded collaborative project.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
InnoUp Farma competitors and assessment
Company assessmentDirect peers
- Matinas BioPharma: Clinical-stage biopharma developing an oral drug delivery platform (MAT2203 oral amphotericin B) using a lipid nanocrystal technology. Closest comparable to InnoUp's nanoparticle platform approach of converting IV or poorly bioavailable drugs to oral formulations.
- DBV Technologies: Develops Viaskin epicutaneous immunotherapy, including Viaskin Peanut for peanut allergy desensitization. Directly comparable to INP20 as a non-oral (patch-based) immunotherapy alternative for the same indication.
- Selecta Biosciences (Cartesian Therapeutics): Develops nanoparticle-based immunomodulation therapies (e.g., ImmTOR tolerance platform). Comparable to InnoUp's nanoparticle approach to modulating immune responses for vaccines and immunotherapy applications.
- NanoCarrier: Japanese clinical-stage company developing polymeric micelle nanoparticle drug delivery systems for oncology (e.g., NC-6004 cisplatin). Comparable technology class to InnoUp's polymeric/biocompatible nanoparticles for low-bioavailable drugs.
Emerging players
- Aravax: Clinical-stage company developing peptide-based immunotherapy (PVX108) for peanut allergy. Directly comparable to INP20 as an emerging peanut allergy immunotherapy player using a different delivery modality.
- Arcturus Therapeutics: Clinical-stage company developing lipid nanoparticle (LNP) delivery systems for mRNA therapeutics and vaccines. Comparable to InnoUp's INP30 oral vaccine program as a nanoparticle-enabled vaccine delivery company with overlapping technology class.
- Intrommune Therapeutics: Clinical-stage company developing oral mucosal immunotherapy (OMIT) for food allergies including peanut. Directly comparable to INP20 as an oral immunotherapy approach to peanut allergy.
- CytImmune Sciences: Clinical-stage company developing tumor-targeted gold nanoparticle therapeutics (Aurimune). Comparable nanoparticle drug delivery platform focused on oncology, similar in technology class to InnoUp's INP12.
- Esperovax: Early-stage company developing oral vaccine delivery technology. Comparable to InnoUp's INP30 oral SARS-CoV-2 vaccine program and overall platform emphasis on oral vaccine administration.
Broad incumbents
- Nanobiotix: Late-stage French biotech developing nanoparticle-based oncology treatments (e.g., Hensify radioenhancer). Comparable nanoparticle therapeutic platform but focused on intratumoral injection rather than oral delivery; broader and better-capitalized than InnoUp.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
InnoUp Farma social profiles
Digital presenceInnoUp Farma compliance and trust
Trust signalCompliance1 record
InnoUp Farma financial estimates
Financial estimateRevenue estimate
Valuation estimate
InnoUp Farma leadership team
Management profileNumber of profiles
Profiles17 records
InnoUp Farma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InnoUp Farma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InnoUp Farma
What does InnoUp Farma do?
InnoUp Farma is a clinical-stage biopharmaceutical company that develops oral drug delivery products based on a proprietary, patented Nanoparticle Platform of biocompatible, high-bioadhesive particles. It is advancing three programs: INP12 (oral paclitaxel for breast cancer, Phase I approved), INP20 (oral peanut allergy immunotherapy, Phase I in development), and INP30 (oral SARS-CoV-2 vaccine, preclinical). The platform is designed to increase bioavailability, reduce toxicity and enable mucosal vaccination/immunotherapy, and has been scaled to industrial production.
Is InnoUp Farma a public or private company?
InnoUp Farma is a private company. It is classified as venture growth investor backed and is currently operating.
When was InnoUp Farma founded?
InnoUp Farma was founded in 2013. It employs 11 to 50 people.
Where is InnoUp Farma based?
InnoUp Farma is headquartered in Noáin, Spain, in the Europe region.
How does InnoUp Farma make money?
Two revenue lines are on record. Drug Development and Licensing is the primary driver. The others are government Grants and Research Funding.
Who are InnoUp Farma's main competitors?
Direct peers on record are Matinas BioPharma, DBV Technologies, Selecta Biosciences (Cartesian Therapeutics) and NanoCarrier. Emerging players are Aravax, Arcturus Therapeutics, Intrommune Therapeutics, CytImmune Sciences and Esperovax. Nanobiotix is listed as a broad incumbent.
Does InnoUp Farma have an API?
No public API is recorded for InnoUp Farma.
What industry is InnoUp Farma in?
InnoUp Farma's product category is Nanopharmaceuticals / Oral Drug Delivery Therapeutics. Its primary akta.pro industry code is HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 325414 and its SIC code is 8731.